Oxepanoprolinamide
Chemical compound
Oxepanoprolinamide[edit | edit source]
Oxepanoprolinamide is a synthetic chemical compound that belongs to the class of antibiotics. It is a derivative of the oxepane ring system, which is a seven-membered heterocyclic compound containing one oxygen atom. Oxepanoprolinamide is notable for its potential use in treating bacterial infections, particularly those caused by antibiotic-resistant bacteria.
Chemical Structure and Properties[edit | edit source]
Oxepanoprolinamide is characterized by its unique chemical structure, which includes an oxepane ring fused to a prolinamide moiety. This structure is responsible for its biological activity and its ability to interact with bacterial ribosomes, inhibiting protein synthesis. The presence of the oxepane ring is a distinguishing feature that contributes to its stability and efficacy as an antibiotic.
Mechanism of Action[edit | edit source]
The primary mechanism of action of oxepanoprolinamide involves binding to the bacterial ribosome, a critical component of the protein synthesis machinery. By binding to the ribosome, oxepanoprolinamide disrupts the translation process, preventing the synthesis of essential proteins required for bacterial growth and survival. This mechanism is similar to that of other ribosome-targeting antibiotics, but the unique structure of oxepanoprolinamide allows it to overcome certain resistance mechanisms that affect other drugs.
Clinical Applications[edit | edit source]
Oxepanoprolinamide is being investigated for its potential use in treating infections caused by multi-drug resistant bacteria, including strains of Staphylococcus aureus and Escherichia coli. Its ability to target resistant bacteria makes it a promising candidate for inclusion in the arsenal of antibiotics used to combat difficult-to-treat infections.
Development and Research[edit | edit source]
Research into oxepanoprolinamide is ongoing, with studies focusing on its efficacy, safety, and pharmacokinetics. Preclinical trials have shown promising results, and further studies are needed to determine its potential for clinical use. The development of oxepanoprolinamide is part of a broader effort to address the growing problem of antibiotic resistance by developing new drugs with novel mechanisms of action.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD